Interesting attempt at a flip. I seem to remember multiple posts pointing out critics of the JAMA analysis had either business ties or research grants coming from competitor regimens, seems to be a good deal of intellectual dishonesty going on here. I’ll stick with the +60 or so Neuro oncologists and researchers lending their names to the JAMA analysis, along with the long term +50,000 long investors / “bag holders”. Thanks for weighing in at the last minute and attempting to save all of us.
—. —- —-
Not intended as investment advice, do your own due diligence.
Market Data 
Markets 
AI
